Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    518 result(s) found for: pancreatic cancer. Displaying page 7 of 26.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2015-002001-11 Sponsor Protocol Number: D4198C00001 Start Date*: 2015-12-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    Medical condition: Adult patients (aged ≥18 years) with histologically or cytologically confirmed metastatic PDAC, and had tumor progression following prior standard first-line 5-FU-containing or gemcitabine-containi...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001625-40 Sponsor Protocol Number: AX-CL-PANC-PI-008619 Start Date*: 2019-10-21
    Sponsor Name:GWT-TUD GmbH
    Full Title: A MULTICENTER, PHASE I/II STUDY OF SEQUENTIAL EPIGENETIC AND IMMUNE TARGETING IN COMBINATION WITH NAB-PACLITAXEL/GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
    Medical condition: Pancreatic Ductal Adenocarcinoma (PDAC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001568-66 Sponsor Protocol Number: A4061028 Start Date*: 2007-08-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A randomized, double-blind phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pan...
    Medical condition: Unresectable or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SE (Completed) GB (Prematurely Ended) FR (Completed) PT (Completed) AT (Prematurely Ended) HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005774-37 Sponsor Protocol Number: GETNE-2016-01 Start Date*: 2016-04-29
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos. SECRETARÍA TÉCNICA GETNE (GETNE)
    Full Title: Phase II study to evaluate efficacy of rechallenge with Sunitinib in Patients with Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic who previously ...
    Medical condition: Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003547-29 Sponsor Protocol Number: 04-22 Start Date*: 2012-10-17
    Sponsor Name:Onconova Therapeutics Inc.
    Full Title: A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metas...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003042-20 Sponsor Protocol Number: ET21-169 Start Date*: 2022-06-21
    Sponsor Name:Centre Léon Bérard
    Full Title: PARPi-PANC - A multicentric, single arm, phase II trial assessing the efficacy of niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
    Medical condition: Patients with metastatic homologous repair-deficient pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003639-37 Sponsor Protocol Number: D4198C00003 Start Date*: 2017-03-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    Medical condition: Adult patients (aged ≥18 years) with histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma who are treatment naive or have tumor progression following prior standard...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000053-30 Sponsor Protocol Number: A4061016 Start Date*: 2005-07-21
    Sponsor Name:Pfizer Inc. - La Jolla laboratories
    Full Title: A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portion
    Medical condition: Treatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreas
    Disease: Version SOC Term Classification Code Term Level
    5.1 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003768-30 Sponsor Protocol Number: IEO906 Start Date*: 2019-11-12
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumors
    Medical condition: Pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001925-28 Sponsor Protocol Number: FGCL-3019-087 Start Date*: 2020-03-11
    Sponsor Name:FibroGen, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanc...
    Medical condition: Locally Advanced, Unresectable Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Restarted) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003496-54 Sponsor Protocol Number: FOOTPATH Start Date*: 2019-01-16
    Sponsor Name:University Hospital, LMU Munich (Germany)
    Full Title: A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH)
    Medical condition: Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 8 of 201622: each T, each N, M1]
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004860-12 Sponsor Protocol Number: ERCAVATAR2015 Start Date*: 2016-02-24
    Sponsor Name:Centro Nacional Investigaciones Oncológicas (CNIO)
    Full Title: Integrated Genomics and Avatar Mouse Models for Personalized Treatment of Pancreatic Cancer
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001609-81 Sponsor Protocol Number: PH-L19ILGEM-01/07 Start Date*: 2007-11-05
    Sponsor Name:Philogen S.pA.
    Full Title: Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer
    Medical condition: Histologically or cytologically confirmed solid cancer of any pathology or adenocarcinoma of the pancreas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065147 Malignant solid tumor LLT
    9.1 10052747 Adenocarcinoma pancreas LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021872-27 Sponsor Protocol Number: ICO-20431 Start Date*: 2010-12-27
    Sponsor Name:Institut Català d’Oncologia (ICO)
    Full Title: “Estudio de fase II de tratamiento neoadyuvante con gemcitabina, Tarceva® y oxaliplatino, seguido de quimiorradioterapia con Tarceva® y gemcitabina en pacientes con adenocarcinoma pancreático de re...
    Medical condition: ADENOCARCINOMA DE PANCREAS
    Disease: Version SOC Term Classification Code Term Level
    13 10050255 Neoplasia del pancreas NEOM LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004022-87 Sponsor Protocol Number: A6181111 Start Date*: 2007-04-05
    Sponsor Name:Pfizer Inc. [...]
    1. Pfizer Inc.
    2. Pfizer bv CR
    3. Pfizer bv RA
    Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS
    Medical condition: Progressive, advanced/metastatic well-differentiated pancreatic islet cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033632 Pancreatic neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended) BE (Completed) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006260-29 Sponsor Protocol Number: CIOCC 012007 Start Date*: 2008-02-22
    Sponsor Name:Fundación Hospital de Madrid
    Full Title: "Estudio farmacodinámico Fase "0" de Micofenolato Mofetil (MMF, CellCept) en pacientes con cáncer de pancreas"
    Medical condition: Cáncer de Pancreas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014407-31 Sponsor Protocol Number: 09.07 Start Date*: 2009-10-06
    Sponsor Name:Odense Universitetshospital
    Full Title: Randomiseret fase II forsøg med irinotecan, cetuximab og everolimus (ICE) sammenlignet med capecitabin og oxaliplatin (CapOx) til patienter med gemcitabin resistent pancreascancer.
    Medical condition: Patienter med gemcitabin resistent pancreascancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005386-35 Sponsor Protocol Number: GI-4000-02 Start Date*: 2008-10-07
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant...
    Medical condition: Pancreatic Cancer, post resection R0/R1 status, with tumor sequence confirmation of Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023183-40 Sponsor Protocol Number: CSOM230I2201 Start Date*: 2011-06-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu...
    Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016875-30 Sponsor Protocol Number: VA 2009/40 Start Date*: 2010-04-12
    Sponsor Name:CRLC VAL D’AURELLE
    Full Title: Essai de phase II évaluant l’association de gemcitabine, trastuzumab et erlotinib en 1ère ligne de traitement par chimiothérapie des patients atteints d’un adénocarcinome du pancréas métastatique
    Medical condition: adénocarcinome du pancréas métastatique
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 10:02:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA